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Abstract
Lipid peroxidation is one of the primary events of the cell injury process. In 
pathophysiological condition, it is undergoing the initiation of organ damage. 
Various free radicals are playing a key role in this lipid peroxidation process. Free 
radical associated organ damage involves the three major phases, that is, initiation, 
propagation and termination. The primary source of various free radical forma-
tions is mediated through the pathophysiological function of mitochondria. Lipid 
peroxidation is contributed to the multiple neurodegenerative disorders. Thus, the 
various endogenous cellular anti-oxidant systems are regulated lipid peroxidation  
process and control the neurodegenerative action. Some of the molecules are 
targeted to attenuate the lipid peroxidation and their mediators for the prevention 
of neurodegeneration.
Keywords: malondialdehyde, vascular dementia, Alzheimer disease,  
multiple sclerosis
1. Introduction
Lipid peroxidation (LPO) is a complex process of the cellular system. The 
reactive oxygen species (ROS) such as superoxide anion, hydroxyl radical and 
hydrogen peroxide radicals play a key role in the process of lipid peroxidation [1]. 
Oxygen radicals, that is, superoxide anions are a primary bioactive molecule in LPO 
process. LPO process releases the various metabolic intermediated products such as 
malondialdehyde (MDA) and 4-hydroxynonenal (HNE) [2]. Further, the accumu-
lation of LPO products; even it is small amounts induces the cell death process via 
multiple cell signaling process [3, 4]. ROS are ready to attack/interact with various 
bio molecules like polyunsaturated fatty acids (PUFA) of the fatty acid membrane. 
Then, LPO products are initiating the multiple self-propagative chain reactions 
[5]. This LPO associated destruction of membrane lipids and their intermediate/
end-products are potentially dangerous for the various cells, tissues and organs. 
However, the LPO process is overcome by the cellular enzymatic system such as 
catalase (CAT) & superoxide dismutase (SOD); and non-enzymatic molecules like 
vitamins A and E [6]. Thus, lipid peroxidation is a self-propagating chain-reaction 
and involves the multiple ways of LPO product formation; so the availability of few 
lipid products can cause the significant tissue damage [7]. However, the extensive 
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research about the lipid peroxidation process and products are not yet been studied. 
The precise action and regulatory function of LPO in various pathophysiologi-
cal conditions of neurodegenerative disorders such as Alzheimer disease (AD), 
dementia, Parkinson disease (PD), Huntington disease (HD), multiple sclerosis 
(MS), amylotropic lateral sclerosis (ALS), stroke and neuropathy are needed to be 
investigated [8, 9]. This book chapter is focused on the role of the lipid peroxidation 
process in neurodegenerative disorders.
2. Relationships of free radicals and LPO
LPO occurs due to the generation of free radicals process in the biological 
system. The free radicals are readily attacking the phospholipids of cell mem-
brane leads to degrading the lipids action [10]. This rapid reaction towards lipid 
membrane is due to the availability of multiple double bonds between methylene 
(▬CH2▬) bridges and reactive hydrogen atoms. This is most frequently occurs 
with polyunsaturated fatty acids (PUFA) [11]. The free radical reactions are 
self-perpetuating chain reactions and it is highly reactive molecules with a various 
biomolecule such as protein, lipids, mitochondria, endoplasmic reticulum and 
DNA due to its unpaired electrons [12]. In addition, these radicalsare existed very 
short duration, that is, 10−9–10−12 second. However, before diverging of these free 
radicals are reacts with another molecule; to make their own stability by attracting 
or donate the electrons [13]. Generally, controlled generation of free radicals under 
normal body condition is good for the physiological process; because it enhances 
the immune cell activation and stimulates the various cellular systems.
Unfortunately, the large quantity of free radical generation causes the cell death. 
The abundant generation of free radicals is occurred due to abnormal metabolic 
and homeostatic functions. Normally the raising of free radicals is controlled by 
various endogenous anti-oxidant defense systems. There are two major factors are 
employing the activation of free radical associated lipid peroxidation process. The 
primary factor is increasing of cytosolic free radical concentration and it occurs 
due to enzymatic and mitochondrial mediated reactions [14]. Another factor is 
the reduction anti-oxidant fence system and it occurs due to the changes in the 
normal endogenous enzymatic pool. The imbalanced action of free radicals ate 
responsible for the LPO. LPO process not only occurs in cell membrane lipids; it 
also occurs in mitochondria, endoplasmic reticulum and nuclear membrane. This 
intracellular reaction of LPO is enhancing the cell death process [15]. Later stage 
of LPO process is also enhanced release of various biomolecules which activates 
the paracrine actions. The overall effect is procuring the organ and system failure. 
Here some of the examples are listed for the lipid peroxidation associated disorders 
such as cancer, atherosclerosis, myocardial infarction, coronary artery disease, liver 
failure, renal failure and autoimmune disease. In addition, the numerous reports are 
documented that, LPO process also enhances the pathogenesis of neurological dis-
orders such as Alzheimer’s disorder; Parkinson disease; multiple sclerosis, vascular 
dementia, stroke and neuropathic pain [16].
3.  Molecular mechanism of free radicals, antioxidant and toxicity 
reactions
The free radical (R*) formation is mainly due to the abnormal bio-activation 
process sometimes due to xenobiotic reactions such as cytochrome P450; prostaglan-
din synthase and lipoxygenase reactions. Free radical associated lipid peroxidation 
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reaction has three stages. (1) Initiation stage: in this stage, free radicals are attacking 
the covalently bonded molecules due to its high affinity [17]. The covalent bond 
containing bio-molecules are DNA, proteins, lipids and phospholipids. The mem-
brane phospholipids, that is, PUFA is a primary target in the cellular system. In this 
stage fatty acid radical, that is, lipid radical (L*) is produced. (2) Propagation stage: the 
primary noticeable initiators of propagation stage of free radicals are reactive oxygen 
species (ROS; i.e., OH• and HOO•). This stage another lipid radicals, that is, lipid 
peroxy radical (LOO*) and lipid hydroperoxide (LOOH) are produced. Here, LOOH 
is non-radical. Whereas, when radicalsreact with non-radical molecules; non-radical 
molecules ready to changes their own property lead to form another active radical. 
This process is called as “chain reaction mechanism”. (3) Termination stage: in this 
stage; different molecules are involved to speed up termination free radical—LPO 
reaction by neutralizing free radicals such agent is also called antioxidants such as 
vitamin E and vitamin C. Some of the anti-oxidants molecules are presents within the 
body like superoxide dismutase, catalase and glutathione peroxidase. These molecules 
are actively converting the LOO* and LOOH molecules to stable lipid alcohol (LOH). 
It is non-toxic to the biological system. Generally, the radical reaction stops when two 
radicals are reacted and produces the non-radical species. However, these reaction-
sare happening, when the concentration of radical species is higher. In pathological 
conditions, the failure of the termination stage of LPO process leads to produce the 
multiple lipid peroxidative products [18–20]. The free radical (R*) associated lipid 
peroxidation in two different phases. The first phase is the lipid phase; it occurs in 
the cell membrane. The second phase is an aqueous phase; it occurs in the cytosolic 
region of the cell. Antioxidants are regulated inboth phases of the LPO process [21].
Figure 1. 
This illustration is showing the reactions between free radicals, lipids and antioxidant molecules. Mechanism of 
LPO process and lipid radical associated neurotoxicity are undergoes the following actions, that is, initiation, 
propagation and termination. Whereas, the propagation stage of lipid radicals are induce the formation of 
various lipid radicals. Finally, it interacts with multiple levels of biomolecular changes leads to cause the 
neurodegeneration.
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In lipid phase, PUFA methylene (▬H▬) bridges are converts to PUFA oxy 
(▬OO*▬) radical. An antioxidant such as tocopherol (Toc-OH) induces the PUFA 
oxy (▬OO*▬) radical conversion to PUFA oxy (▬OOH▬) molecule. PUFA 
peroxy (▬OOH▬) bridged molecule biologically non-toxic. Further nontoxic 
PUFA peroxy (▬OOH▬) bridged molecules are converted to PUFA peroxy 
(▬OOH*▬) molecule with the action of phospholipase A2 (PLA2). In this process 
is shifting the lipid phase to the aqueous phase of the reaction [22]. The PUFA 
peroxy (▬OOH*▬) molecules are toxic to the cellular system [23]. These molecules 
are regulated by two endogenous enzymatic anti-oxidant systems such as catalase 
and glutathione peroxidase. Catalase is directly converting the PUFA peroxy 
(▬OOH*▬) molecules to PUFA peroxy (▬OH▬) molecules. Glutathione peroxi-
dase enhances the neutralizing of PUFA peroxy (▬H2O2▬) molecules with the help 
of selenium (Se). In the cytosol, the superoxide accumulation occurs due to the ETC 
reaction and other mitochondrial reactions. The aqueous phase superoxide ions 
are neutralized by superoxide dismutase enzyme. The failure of free radical—LPO 
reactions leads to activates cell death; proximal and distal tissue damage; and organ 
failure process [24]. The interaction of free radical, lipid peroxidation and toxicity 
mechanism is showed in Figure 1.
4. By-products of lipid peroxidation
The LPO of unsaturated lipids and ROS attack on unsaturated lipids are produc-
ing the variety of oxidation products. The primary oxidation products of lipid are 
lipid hydroperoxides (LOOH). In addition, The LPO process releases the additional 
by-products via metabolic conversion of lipids and their radicals. By-products of 
LPO are reactive aldehydes like malondialdehyde (MDA), 4-hydroxynonenal (HNE) 
propanal and hexanal. MDA is identified as the potent mutagenic product of lipid 
peroxidation; whereas, another LPO products, that is, HNE is toxic to the cellular 
system but not mutagenic. LPO products are categorized into two ways; first one 
is primary LPO product, that is, LOOH and their adduct products. Another one 
is the secondary LPO product, that is, MDA and their adducts [25]. Primary lipid 
peroxidation products (hydroperoxides) are formed at the propagation phase of the 
LPO process. The hydroperoxide group can be attaching to multiple lipid molecules 
such as free fatty acids; triacyl glycerols; phospholipids; and sterols. LOOH are more 
stable products and found in serum. Hence, the LPO products can be detectable for 
identification of cellular oxidative stress. The LOOH are targeted to various reduc-
tion reactions; which lead to either inhibition of peroxidative damage and/or induc-
tion of peroxidative damage [3]. The inhibition of peroxidative damage is due to 
decomposing of hydroperoxides, namely two-electron reduction [26]. Some of the 
enzymes are responsible for this two-electron reduction process of hydroperoxides. 
Those enzymes are selenium-dependent glutathione peroxidases (GPx) and seleno-
protein P (SeP). The induction of peroxidative damage is due to decomposing of 
hydroperoxides, namely one-electron reduction in the initiation and/or propagation 
steps of LPO process [27]. These conditionsenhance the formation of new LOOH, 
that is, lipid peroxyl radical and alkoxyl radicals by redox cycling process [28].
A secondary lipid peroxidation product (MDA) is a by-product of arachidonic 
acid and PUFAs decomposition. This reaction occurs by enzymatic or non-enzy-
matic reaction process. MDA has a dose-dependent dual role function; it is chemi-
cally stable and membrane-permeable compare to ROS; whereas, MDA is less toxic 
than HNE and methylglyoxal (MG) products. The enzymatic production of MDA 
is occurred during the biosynthesis of thromboxane A2 (TAX-A2) from arachi-
donic acid metabolism by the action of TAX-A2 synthase [29]. The non-enzymatic 
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production of MDA occurs with a mixture of lipid hydroperoxides during lipid 
peroxidation process. The non-enzymatic production of MDA is occurring under 
specific conditions. The metabolism of MDA involves via mitochondrial aldehyde 
dehydrogenase actions; which leads to form decarboxylated products, that is, 
acetaldehyde; and it is further oxidized by aldehyde dehydrogenase to form acetate; 
carbon-di-oxide (CO2); and water (H2O) [3].
Both primary and secondary by-products of LPO are playeda key role in the 
various pathophysiological process including neurodegenerative disorders. MDA 
and HNE products are interfering with the various biological processes such as 
genetic; physiological; and pathological to control the intrinsic and extrinsic factor 
influences [30]. In genetic aspects, LPO can be controlled by diet; environment; 
and habits. Various LPO studies are carried out in experimental animal models. 
The following agents are reported to produce the LPO in the biological system. 
Cumene hydroperoxide, it is used in the chemical and pharmaceutical industry as a 
catalytic agent [31]. Tert butyl hydroperoxide is an organic oxidizing agent and acts 
as a bleaching agent; and initiator of polymerization. Carbon tetrachloride (CCl4) 
is a toxic carcinogenic agent and it is used as a solventfor the industrial degreasing 
operations. In addition, it is also used as pesticides and chemical intermediate of 
refrigerants. Quinolinic acid (QA) is produces the potent neurotoxic metabolite of 
kynurenine metabolism intermediates and involves in the pathogenesis of neurolog-
ical diseases [32]. Furthermore, some of the transition metals ions also play a role for 
LPO process due to its pro-oxidant effect. The major transition metals for the LPO is 
copper; chromium; cadmium; nickel; vanadium; manganese; and iron [3, 33–35].
In aging condition; iron plays a key role in the neurological disorders. Iron 
accumulation in CNS causing the lipid peroxidation process and it causes the 
motor dysfunction and other neurological disorders [36]. Now, iron dependent cell 
death is linked with the lipid peroxidation process. This phenomenon also called 
as “ferroptosis”. Ferroptosis is a process and produces the non-apoptotic manner of 
cell death regulation process [37]. This iron dependent regulation of cell death is 
characterized by the accumulation of LPO products. Moreover, ferroptosis process 
can be controlled by the lipid acting antioxidants and potent iron chelators [37, 38]. 
Some of the molecules are identified as ferroptosis regulators such as erastin and rat 
sarcoma selective lethal 3 (RSL3) proteins [39].
5. Hazards action of lipid peroxidation products
The developed LPO products must be degraded in the biological system by 
enzymatic and non-enzymatic manner. If the termination of oxidized LPO prod-
ucts is not enough; it’s causing the potential tissue damage to the cell membrane. 
The first phase of LPO is altered by the cytosolic enzymatic and calcium pool 
[40]. The second phase of LPO is shown to activation of macrophage followed by 
oxidation of PUFA [41, 42]. In addition, LPO products also interact with multiple 
catalysts and heavy metals such as iron and copper metals. A ferrousform of iron is 
highly interactive metals with lipid peroxidative products and it also documented to 
produce the potent neurodegenerative process [33, 42].
The summary of LPO induced neurodegeneration is due to free radical associ-
ated activation of membrane lipid oxidation and subsequent alteration of free radi-
cal, mineral, metal and enzymatic pool activation in the cytosol of every cellular 
system including nervous tissue [42, 43]. In a neuron, these actions are rapid and 
specialized targeted proteins, that is, cytoskeleton, misfolding and prion proteins 
[44]. Some of the actions occur in mitochondria and nuclear levels [45]. This mul-
tiple molecular and cellular actions are responsible for the sustained activation of 
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the neurodegenerative process leads to produce the multiple neurological disorders 
with neurodegeneration [46, 47]. This hazards reaction of LPO on targeted biomol-
ecule for neurodegenerative disorders are illustrated in Figure 2. The following sec-
tion is explaining about the LPO role in neurodegenerative disorders like Alzheimer 
disease (AD), Parkinson disease (PD), multiple sclerosis (MS), amylotropic lateral 
sclerosis (ALS), stroke and neuropathy.
6. Role of LPO in Alzheimer disease
LPO is one of the primary key factors for the progress of neurodegenerative 
disorders. The pathogenesis of AD is also documented that, oxidative stress enhance 
the progress of neurodegeneration via free radical associated LPO reactions [48]. 
The progress of AD rate is higher in developing countries and it causes the reduc-
tion of quality of life [49]. The various etiological factors are identified in the devel-
opment of AD such as smoking, alcohol, hypertension, atherosclerosis, diabetes, 
hypercholesterolemia, aging and trauma. In addition, specialized neuronal proteins 
such as amyloid precursor protein (APP), the Aβ peptide, neurofibrillary tangles, 
Tau proteins, and amyloid plaques are plays a role in the alteration of neuronal 
function and its enhance the neurodegeneration and development of AD [50, 51]. 
Furthermore, these changes are due to alteration of multiple cellular signaling cas-
cades such as over activation of α, β and γ secretase; beta-site APP-cleaving enzyme 
1 and 2 (BACE1 & BACE2); presenilins proteins 1 and 2 (P1 & P2); apolipoprotein 
E-epsilon4 variant (ApoE-ε4); alpha2-macroglobulin; and calcium dependent 
kinases [49, 52–55]. LPO and their metabolites contribute to the development of 
Figure 2. 
Mechanism of LPO associated neurodegenerative disorders. The initial event of free radicals enhances the lipid 
peroxidation of products, which leads to alter the ion channels; enzymes; genes and proteins. The net effects of 
LPO products are cause the Alzheimer disease (AD); dementia; Parkinson’s disease (PD); Huntington disease 
(HD); multiple sclerosis (MS); amylotropic lateral sclerosis (ALS); stroke; and neuropathy.
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neurovascular complication and neurodegeneration by activation of the above 
signaling pathways. Recently, ferrous ion dependent free radical generation, lipid 
peroxidation and activation of amyloid proteins are responsible for the develop-
ment of AD [56]. The classical medicines of nootropic agents like donepezil; 
rivastigmine; galantamine; and memantine are enhanced the memory function 
[57]. Some of the agents are anti-inflammatory agent such as zileuton is regulated 
in the neurodegenerative process via anti-lipidperoxidative and anti-inflammatory 
actions [58]. However, there are limited studies reported that anti-lipid peroxidative 
agents are ameliorated the AD [59, 60].
7. Role of LPO in dementia
Dementia is one of the leading causes of changes in quality of life and death. 
Now a days, various pathophysiological factors are employed in the progression 
of dementia especially VaD; such conditions are hypertension, diabetic mellitus, 
renal failure, cardiac failure and bone fracture [61–63]. The hallmark of dementia is 
still complicated and some of the reports revealed that α-synuclein protein altera-
tion enhances the neurodegeneration and dementia symptoms [64]. In addition, 
the genetic predisposition is identified as causing factors for dementia disorders. 
Recently, some of the newer molecular proteins are explored in the neurodegenera-
tion as well as dementia such proteins are α-synuclein, ubiquitin, parkin, neurofila-
ments and chaperone proteins. These all changes are observed in the moderate 
and chronic condition of dementia disorders. Whereas, the initial effects of the 
neurodegeneration process is to express the development of free radical and LPO 
associated oxidative stress environments in the nervous system [18]. However, the 
specific molecules for the LPO regulators are not studied in dementia disorders. 
Whereas, numerous studies revealed that, the memory enhancing drugs like done-
pezil; rivastigmine; galantamine; and mementine are reduced the lipid peroxidative 
products reaction. Hence, the direct and specific modulatory agents are required for 
the management of dementia disorders [65]. Further, dementia disorders are arising 
with multiple pathophysiological factors; so the multi-targeted drug approaches 
will be more effective to prevent the dementia disorders. Here, the LPO targeted 
drugs is one of the primary facts for the treatment of dementia disorders.
8. Role of LPO in Parkinson disease
Parkinson disease (PD) is one of the extrapyramidal disorders and it occurs due 
to dopaminergic neurodegeneration and alteration of dopamine levels in the brain. 
Symptomatically, it affects the motor neuron and produces the abnormalities of 
body movements. The LPO process induces the primary form of sporadic type of 
Parkinson disease (PD) [66]. Mainly, dopaminergic neuron damage occurs in the 
substantia nigra, locus ceruleus, dorsal motor nucleus and substantia innominata 
[67]. The sign of movement problems is festinating gait; rigidity of limbs; poverty 
of voluntary movement; and rolling type of tremor. The progressiveness of PD is 
very slow [68]. The various types of cells are employed in the dopaminergic neu-
rodegeneration such as neutrophils; macrophages; and astrocytosis [69]. This all 
process is altered by free radicals and lipid peroxidative reactions. LPO reactions 
affect multiple biomolecules such as such as membrane lipids, proteins (especially 
α-synculein); mitochondrial pore; endoplasmic reticulum; liposomes; peroxisomes; 
lysomes including DNA and RNA [51]. Therefore, the reduction and controlling 
LPO process is able to treat the PD. However, the limited agents are tested in the 
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management of dopaminergic neurodegeneration. Hence, the more extensive stud-
ies are required for the treatment of PD with direct and specific anti-lipid peroxida-
tive drugs or combination with subsequent cell signal arresting molecules [70, 71].
9. Role of LPO in Huntington disease
Huntington disease (HD) is one of the autosomal dominant diseases. And, it is 
also one of the neurodegenerative disorders. It occurs between the age of 20 and 
50 years. The symptoms of HD are a chorei form of body movements; dystonia; the 
paucity of movement and progressive loss of neuron [45]. Genetically, it affects  
the 4th chromosomal gene; huntingtin (HTT) protein mutation and misfold-
ing. The main area of the brain is affection in caudate; putamen nucleous; globus 
pallidus; and nucleus accumbens leads to cause the atrophy of brain via the neuro-
degenerative process [32, 72]. The microscopical observation revealed that small 
spiny neurons of the caudate and putamen cause the astrocytosis. The chronic event 
of cellular neurodegenerative process enhances the neuronal oxidative stress with 
an accumulation of free radicals and LPO process [73]. During the early stage of 
LPO process; neuronal cells losses the cell contents; shrinkage of caudate nucleo-
lus; shrinkage and dilatation of the anterior horns of lateral ventricles [45, 72]. 
Moreover, LPO process enhances the alteration of various neurotransmitters such 
as a gamma aminobutyric acid (GABA); acetylcholine; and substance P [74, 75]. 
The various medicines are reported to treat the HD via inhibition of LPO process 
[76]. Therefore, LPO targeted medicines are useful for the management of HD and 
neurodegenerative disorders.
10. Role of LPO in multiple sclerosis
Multiple sclerosis (MS) is a known demyelinating disease and its causes the dys-
function of the central nervous system. Myelin produces the insulation coating on 
the nervous system like electrical wires. The pathogenesis of MS is shown by attacks 
of neuronal proteins of CNS such as myelin proteins. In addition, the LPO products 
are play key role in the pathogenesis of MS [77]. This myelin protein is essential 
for neuronal function because of its support of the neuronal signal conduction 
without loss of strength. Whereas, the loss of myelin proteins by immunological 
abnormalities are cause the neuronal dysfunction and symptoms of MS. Further, 
these neuronal damages are permanent and difficult to the MS [78]. The symptoms 
of MS are numbness or weakness in limbs, one side of your body, legs and trunk; 
partial or complete loss of vision and double vision; tingling and pain; tremor, lack 
of coordination, unsteady gait, slurred speech, fatigue, dizziness; and bowel and 
bladder function. These all symptoms are due to damage of myelin proteins of CNS 
[79]. The various factors are employed in the pathogenesis of MS such as genetic 
abnormalities; environmental factors (smoking and alcohol); and autoimmune 
disease (thyroid disease, type 1 diabetes and inflammatory bowel disease) [80]. The 
MS is a progressive demyelinating process, which is due to the over the action of 
the immunological system. The immunological proteins are inducing the multiple 
physiological processes. Whereas the over activity of immunological proteins causes 
the neurological damage via activation of the demyelinating process [81]. This 
chronic progressive is due to the free radical and LPO process. The limited drugs are 
used for the treatment of MS and it also documented that, reduce the LPO products 
accumulation. However, the LPO targeted drugs are not tested in MS disease. So, 
extensive studies are required LPO targeted medicine for the treatment of MS.
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11. Role of LPO in amylotropic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is another neurodegenerative disorder of a 
nervous system and it affects the CNS nerve cells. In addition, it affects the neu-
ronal transmission between the brain and the spinal cord. This leads to affects the 
neuromuscular function and produces the trouble for walking, running and writ-
ing; and speech problems [82]. In addition, it also produces the respiratory failure; 
it is a very serious complication of ALS. The primary target of neurological damage 
is upper motor neurons of cranial motor nuclei, and Betz cells of neocortex lead to 
produce the muscle atrophy and astrocytosis [83]. Sometimes ALS is also produced 
in the lateral column degeneration with gliosis; so it is called “sclerosis”. The pri-
mary etiology of ALS is due to the mutations of superoxide dismutase-1 (SOD1) 
gene [78]. The SOD gene associated proteins are responsible for the reduction of 
cellular free radicals leads to reduce the LPO products associated with protein and 
DNA damage [74, 84]. Therefore, LPO targeted drug is essential for the treatment 
of ALS. However, there is no report is documented for the treatment of ALS.
12. Role of LPO in stroke
Stroke is one more neurodegeneration disorders and it occurs due to the cerebro-
vascular accidents. The primary symptoms of stroke are a cluster headache, motor 
impairment, paralysis and death [85–87]. The various risk factors are employed in 
the pathogenesis of strokes such as smoking, alcohol, obesity, trauma, hyperten-
sion, diabetes and renal failure [88, 89]. In addition, various physiological processes 
are altered with multiple ethiological factors such as hypoxia, ischemia, aneurysm 
and immune activation leads to platelet activation, thrombosis, immune cell activa-
tion decreasing of ATP content, mitochondrial damage, ionic imbalance and glial 
cell activation [90–92]. Furthermore, the chronic neurological damage is due to the 
accumulation of lipid peroxidative products leads to damage to the neurological 
system leads to produce the stroke symptom [93, 94]. The free radical and LPO are 
well documented to produce neurodegeneration in stroke condition [95]. However, 
the tested compounds are show in the alteration of LPO products in the neurologi-
cal system. But, the direct and specific action on LPO products is not documented 
in stroke disorders. So, the extensive studies are required to manage the stroke 
disorders with direct and newer molecule for the reduction of LPO products [96].
13. Role of LPO in neuropathy
The pathogenesis of neuropathy is occurred due to the neurodegenerative 
disorders. In diabetic condition, it produces the multiple types like autonomic 
neuropathy, somatic neuropathy, peripheral and central neuropathy. The etiology 
of neuropathy is due to multiple factors such as ischemia, trauma, hypoxia, free 
radical and lipid peroxidation [9, 97]. These factors alter the cellular and molecular 
events [98, 99]. The anatomy of microvascular system is affecting by the above 
factors and it raising the oxidative stress environment along with DNA damage, 
ATP depletion and activation of ferroptosis [100]. The symptoms of neuropathy are 
the development of autotomy (self-amputation of figures); allodynia (triggering 
of a pain response from stimuli, but it does not provoke pain in normal condi-
tion); hyperalgesia (extreme reaction of painful stimuli); and numbness (unusual 
prickling sensation). The chronic condition of neuronal firing enhances the 
neurodegeneration and reduces the quality of life [101]. In diabetic condition, the 
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specialized etiology involved in the pathogenesis of neuropathy; such factors are 
raising blood glucose, sorbitol, aldose, ketone bodies; and advanced glycation end 
products (AGE) [102]. This all molecules are interlinked with oxidative stress. The 
accumulation of free radicals and the LPO process involves in the all pathological 
situation of neuropathy and neurodegenerative process; which leads to produc-
ing the subsequent activation of ionic imbalance; vascular damage; and neuronal 
damage [103, 104]. The LPO products play a crucial role in the pathogenesis of 
neuropathy [105, 106]. However, the directly acting agents on LPO products and 
specific molecules based actions still need to investigate for the management of 
neuropathy [107].
14. Inhibiting of LPO products
The various approaches are attempted to prevent the LPO products formation. 
There are two approaches are employed in the prevention of LPO products such as 
(1) prevention of LPO products formation by both enzymatic and non-enzymatic 
manner; (2) elimination of LPO products [108, 109]. Prevention of LPO products 
formation is a primary successful method with anti-oxidants such as vitamin C 
and vitamin E are inhibits the LPO [110]. The alternative method of LPO inhibi-
tion is deuteration of PUFA at double bond of methylene bridges (bis-allylic sites) 
leads to reduce the chain reaction process [111]. The major deuteriated PUFAs is 
11,11-D2-ethyl linoleate is identified as suppressing agent for LPO process at low 
level concentration [112]. The primary diagnostic methods for end-products of 
LPO, that is, malondialdehyde (MDA) is thiobarbituric acid reactive substances 
(TBARS) assay. Recently, some immunochemical method is employed for the 
detection of HNE-histidine adducts in biological tissue and fluid samples [113]. 
Based on this basic fundamental of LPO formation and diagnostic procedure; 
some of the molecules are identified for the prevention of LPO process and prod-
ucts formation [114]. Some of the molecules are documented that, it prevents the 
neurodegenerative process via alteration of the various cellular signaling process. 
Some of LPO peroxides are formed by lipoxygenase enzymatic system. Thus, 
5-lipoxygenase (5-LOX) inhibitor, that is, zileuton employed as a reduction of LPO 
products in the biological system via ligation of the active site of iron through its 
N-hydroxy urea moiety [58]. In addition, the 12- and 15-lipoxygenases (12-LOX 
and 15-LOX) process contributes to the significant role in the pathogenesis of neu-
rodegenerative disorders via accumulation of LPO products [115]. The discovery of 
12-LOX and 15-LOX inhibitors is still developing stage. The isotope of deuterated 
of PUFA products are documented to prevents the LPO products via enzymatic 
and non-enzymatic manner [18, 115]. Elimination of peroxides: the limited quan-
tity of LPO products formation and reduction is not harmful to the cellular system. 
Whereas, the abundant accumulation of LPO products makes the serious com-
plication to the biological system via alternating cell signal and functions [116]. 
Generally, the biological system eliminates the LPO products via the enzymatic 
mechanism [117, 118]. The glutathione peroxidase (GPx) enzyme is one of the clas-
sical enzymes for reduction of LPO products. Total eight isoforms of GPx enzymes 
are distributed in humans with different substrate specificities and tissue specific-
ity. Among all GPx enzymes, the GPx4 is identified as a primary enzyme for the 
reduction of lipid peroxides. In addition, it also interferes with ferrous ion leads to 
reduce the ferroptotic cell death and accumulation of toxic lipid peroxides [40]. 
Another cofactor, that is, selenocysteine also helps to enhance the GPx4 enzyme 
activity for reduction of lipid peroxides using due to its strong nucleophilic attack 
on the terminal oxygen of lipid peroxide [119]. This reaction helps to the reduction 
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of hydroxyeicosatetraenoic acid (HETE) or hydroxyoctadecadienoic acid (HODE) 
accumulation in the biological system. Furthermore, selenenic acid intermediates 
are reduced by the two molecules of oxidized glutathione and regenerate the active 
GPx enzyme [120]. List of LPO regulating molecules is listed in Figures 3 and 4.
Figure 3. 
Mechanism of reduction of lipid radicals. The primary event of lipid radicals is ROS formation. Thus, various 
antioxidant molecules are claimed as anti-lipid peroxidative agents. These agents are also known as free radical 
scavengers. This anti-oxidative molecules are categorized into the five ways, that is, enzymatic; non-enzymatic; lipid 
phase; solid phase actions; and activation of metal binding protein actions. The free radical scavenging molecules 
are reduce and termination the lipid radical in the biological system leads to neuroprotection from toxic radicals.
Figure 4. 
Mechanism of LPO modulators for the prevention of neurodegenerative disorders. There are three major 
interrelated functions are inducing the neurodegeneration and neurological disorders such as (1) free radical 
generation; (2) LPO product accumulation; and (3) ferroptosis. The LPO modulators are attenuated the 
neurodegenerative disorders like anti-oxidant; anti-lipid peroxidation; and iron chelating actions.
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15. Summary of LPO in neurodegenerative disorders
LPO products are contributes to the various types of neurodegenerative dis-
orders such as AD, dementia, PD, HD, MS, ALS, stroke and neuropathy [108]. 
However, the availability of LPO products regulating molecules is limited. Their 
molecular action in in-vivo biological actions is not explored yet. Hence, the exten-
sive researches are required to prove the potential ameliorative effect of LPO acting 
molecules to prevent the neurodegenerative disorders.
16. Future directions
Based on this complete literature and research reports, LPO regulating mol-
ecules has ample scope to prevent the neurodegenerative disorders. Because LPO 
products are documented to play a critical role in the various stage of the neuro-
degenerative disease. Even, it also interferes with multiple cell organelles such as 
mitochondria, endoplasmic reticulum, lysosome, peroxisome, nucleus and various 
cytoskeletal proteins. The numerous reports also documented that, the molecules 
are altering the LPO process and reducing the LPO products accumulations. 
Whereas, all the classical neuroprotective drugs are claimed as ion channel regula-
tor; enzyme modulators; receptor antagonist actions so on. The direct and specific 
LPO pathway regulating molecules are not identified to attenuate the neurode-
generative disorders in vivo pharmacological research. Even, the newer concept of 
LPO associated ferroptosis actions enhances the neurodegeneration, but ferroptosis 
regulating molecules in the management of neurodegenerative disorders need to be 
study extensively. So, the discovery of LPO pathway modulating agents can treat the 
neurodegenerative disorders. Hence, we believe that, this book chapter will be help-
ful to the various researchers; who working on newer molecule discovery process 
for the prevention of LPO associated neurodegenerative disorders.
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